Showing results (91-100 of 104) with videos related to

Sort By:
Pageof 11
The Lancet. Oncology|June 29, 2026
SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trialGiulio Francolini, Vanessa Di Cataldo, Saverio Caini, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 23, 2022
Impact of stereotactic body radiotherapy vs palliative radiotherapy on oncologic outcomes of patients with metastatic kidney cancer concomitantly treated with immune checkpoint inhibitors: a preliminary, multicentre experienceGiulio Francolini, Riccardo Campi, Vanessa Di Cataldo, et al.
European Urology Oncology|December 16, 2025
Prostate-specific Antigen Nadir and Time to Nadir Predict Recurrence in Postprostatectomy Patients Treated with Salvage Radiotherapy Without Androgen Deprivation TherapyFederico Mastroleo, Riccardo Villa, Mattia Zaffaroni, et al.
Minerva Urology and Nephrology|January 13, 2021
Health-related quality of life 24 months after prostate cancer diagnosis: an update from the Pros-IT CNR prospective observational studyCarlotta Palumbo, Alessio Bruni, Alessandro Antonelli, et al.
BJR Open|March 25, 2024
Stereotactic prostate radiotherapy with or without androgen deprivation therapy, study protocol for a phase III, multi-institutional randomized-controlled trialMarco Lorenzo Bonù, Alessandro Magli, Davide Tomasini, et al.
World Journal of Urology|March 13, 2019
Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter studyLuca Triggiani, Rosario Mazzola, Stefano Maria Magrini, et al.
European Urology Oncology|April 3, 2023
Salvage Stereotactic Reirradiation for Local Recurrence in the Prostatic Bed After Prostatectomy: A Retrospective Multicenter StudyPaul Archer, Giulia Marvaso, Beatrice Detti, et al.
Cancers|November 27, 2025
Impact of Dosimetric Parameters on Tumor Control in Stereotactic Radiotherapy for Pancreatic Cancer: A Prospective Study on 104 Patients Treated with Simultaneous Integrated Protection (SIP)Marco Lorenzo Bonù, Jacopo Balduzzi, Gloria Pedersoli, et al.
Prostate Cancer and Prostatic Diseases|February 19, 2025
Impact of stereotactic body radiotherapy after progression in castrate resistant prostate cancer patients undergoing first line abiraterone treatment. A subgroup analysis from ARTO trial (NCT03449719)Giulio Francolini, Niccolò Bertini, Vanessa Di Cataldo, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 15, 2025
Re-irradiation in patients affected by prostate cancer and relapsing after previous definitive or postoperative radiotherapy. An international registry based study on behalf of Italian association of radiotherapy and clinical oncology (AIRO). (RE-START)Giulio Francolini, Vanessa Di Cataldo, Saverio Caini, et al.
Pageof 11